Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

MS treatment satisfaction under the microscope: global study launches

NCT ID NCT07504783

Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study aims to understand how satisfied both doctors and patients are with current multiple sclerosis (MS) treatments in everyday medical practice. Researchers will collect information from 261 patients and their physicians across several countries, including the UK, France, Germany, Italy, Spain, China, Japan, and Brazil. The goal is to identify factors that influence satisfaction and how patients feel their current medication compares to previous ones.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

261 people

The number who actually took part.

Started

Jan 2026

Finished

Apr 2026

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Physicians that treat with ofatumumab and MS patients receiving ofatumumab, and who were invited to participate following consultation with their physician.

Ages

18 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Physician inclusion criteria: * Physicians must be actively involved in the treatment/management of patients with MS * Consult with a minimum of 16 MS patients (\>5 in Japan and China, \>10 in Brazil) per month Patient inclusion criteria: Patients for whom physicians complete a Physician Completed Patient Record Form (PRF), and therefore are included in the pool of data for analysis, are based on the following criteria: * Patients who had a physician-made diagnosis of MS before or at the time of data collection * Patients must not currently be involved in a clinical trial * Patients ≥18 years old * For patients included in the ofatumumab sample, they must have been receiving ofatumumab for \>12 months at the time of data collection Exclusion criteria: • None

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Multiple sclerosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

multiple sclerosis Patient Satisfaction Personal Satisfaction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Multiple sclerosis

Contacts and locations

Locations

  • Novartis

    Basel, CH-4056, Switzerland

More trials for these conditions

Other studies related to the condition(s) this trial covers.